Executive Summary: As Principal Investigator, I focus on clinical translation of mass spectrometry-based research into biomedical applications, primarily for lipid metabolites and small molecules. I further oversee projects at the interface of research & commercialization. As Deputy Director, I provide leadership (finance, HR) ensuring resource-efficient & compliant operations. Strategic business development & key liaison with stakeholders (industry, research agencies, tech transfer). Current and past employment history: 2015 - present Principal Investigator, Life Sciences Institute, National University Singapore (NUS) 2015 - present Deputy Director of SLING, Singapore Lipidomics Incubator, NUS 2013 - 2015 Scientific Program Manager of SLING, Singapore Lipidomics Incubator, NUS 2008 - 2013 Senior Research Fellow; YLL School of Medicine, NUS 2004 - 2008 Postdoctoral Research Fellow; YLL School of Medicine, NUS 2003 - 2004 Research Scientist/ Lecturer; Cologne University Bioinformatics Centre, Germany Qualifications: PhD (Biochemistry), U Cologne/ Germany (2003); MSc (Biology), U Greifswald/ Germany (1999); Associate’s Certificate in Project Management, ESI Singapore & Washington U (2011); Entrepreneurship programs, INSEAD Business School (2012), Lean Launchpad NUS Enterprise (2014), NUS Business School (2021) Research Interests: Clinical mass spectrometry, lipidomic applications, human physiological exercise, precision medicine Leadership in Professional Societies, Committees and Boards: ‘Metabolomics’ working group at International Federation of Clinical Chemistry (IFCC) Steering Committee ‘Clinical Lipidomics’ at International Lipidomics Society (ILS) ‘LipidMet’ task group at Metabolomics Society Associate Editor ‘Journal of Mass Spectrometry & Advances in the Clinical Lab’ (JMSACL) Chair & co-founder of ‘Females in Mass Spec’ (FeMS), global network & leadership development Selected Publications: 1) Bendt AK, Mir SA, Maier AB, Goh J, Low IC, Lee JK, Koh AS, Wenk MR, Adamski J. Lessons from the Singapore cohorts showcase symposium—open call for collaborations. Eur J Epidemiol. 2023 Apr 29:1-3. (IF 13.6) 2) Selvalatchmanan J, Wenk MR, Bendt AK. Lipidomics in Clinical Diagnostics. Mass Spectrometry for Lipidomics: Methods and Applications. 2023 Mar 20;2:557-84 3) Vogeser M & Bendt AK. From research cohorts to the patient – a role for “omics” in diagnostics and laboratory medicine? Clin Chem Lab Med 2023. PMID: 36592431 4) Vvedenskaya O, Holčapek M, Vogeser M, Ekroos K, Meikle PJ, Bendt AK. Clinical lipidomics - A community-driven roadmap to translate research into clinical applications. J Mass Spectrom Adv Clin Lab. 2022. PMID: 35199094 5) Burla B, Arita M, Arita M, Bendt AK, Cazenave-Gassiot A, Dennis EA, Ekroos K, Han X, Ikeda K, Liebisch G, Lin MK, Loh TP, Meikle PJ, Orešič M, Quehenberger O, Shevchenko A, Torta F, Wakelam MJO, Wheelock CE, Wenk MR. MSbased lipidomics of human blood plasma - a community-initiated position paper to develop accepted guidelines. J Lipid Res. 2018;59:2001-2017 6) Begum H, Torta F, Narayanaswamy P, Mundra PA, Ji SS, Bendt AK, Saw WY, Teo YY, Soong R, Little PF, Meikle PJ, Wenk MR. Lipidomic profiling of plasma in a healthy Singaporean population to identify ethnic specific differences in lipid levels and associations with disease risk factors. Clin Mass Spec 6 (2017) 25-31 7) Shui G*, Bendt AK*, Jappar IA, Lim HM, Laneelle M, Hervé M, Via LE, Chua GH, Bratschi MW, Zainul Rahim SZ, Michelle AL, Hwang SH, Lee JS, Eum SY, Kwak HK, Daffé M, Dartois V, Michel G, Barry CE 3rd, Wenk MR. Mycolic acids as diagnostic markers for tuberculosis case detection in humans and drug efficacy in mice. EMBO Mol Med. 2012;4(1):27-37 *Equal first author 8) Shui G*, Bendt AK*, Pèthe K, Dick T, Wenk MR. Sensitive profiling of chemically diverse bioactive lipids. J Lipid Res. 2007;48:1976-84 *Equal first author